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Despite recent advances in microscopy techniques, the underlying labeling assays remained mostly 
unchanged. However, super-resolution techniques require other staining conditions than 
conventional light microscopy, like more dense labeling, which is not always trivial to achieve. In 
this work, I present two novel applications of stimulated emission depletion (STED) microscopy to 
the fields of molecular biology and medical diagnostics. For one, I established a fluorescent in situ 
hybridization (FISH) protocol to investigate mRNAs of the three synaptic proteins synaptophysin, 
synaptobrevin, and synaptotagmin in primary hippocampal neurons. This achieved more precise 
information regarding the mRNA numbers and organization than conventional confocal 
microscopy. Secondly, I applied STED microscopy for the development of a novel diagnosis 
method for Alzheimer’s disease (AD). The increased resolution was sufficiently high to 
discriminate low and high molecular weight β-amyloid (Aβ) aggregates produced in vitro. Analysis 
of cerebrospinal fluid (CSF) samples from 36 AD patients, 11 patients with mild cognitive 
impairment (MCI), and 21 controls allowed a separation of AD patients from controls with ~87% 
specificity and ~79% sensitivity. In conclusion, this work illustrates the need for optimization of 
long established methods depending on the imaging technique and sample to obtain more accurate 
data.   
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1. Introduction  
1.1. A brief history of microscopy and imaging 
Throughout history, there has always been a fascination about what the world is composed of. 
However, the human eye can only distinguish two elements if they are at least 0.1 mm apart, 
therefore having a spatial resolution of 0.1 mm (Alberts, 2014). In order to see smaller objects, 
optical tools have been developed, like magnifying glasses or microscopes. Anton van 
Leeuwenhoek could be considered as the inventor of the first compound microscope with a 
sophisticated optical apparatus in the 17th century (Baker, 1739). The first microscopes allowed the 
investigation of biological samples at unprecedented detail. For example, van Leeuwenhoek 
discovered spermatozoa and Robert Hooke described the first plant cells (Hooke, 1665, Baker, 
1739).  
The reason why the sample can be seen under this type of microscopes, bright-field microscopes, is 
based on varying light scattering and absorption properties of the sample that result in contrast 
differences. However, most biological samples have only low contrast rendering detailed 
observations difficult. Staining procedures change the optophysical properties of parts of the 
sample, thereby increasing the contrast. A famous example would be the silver staining invented by 
Camillo Golgi in 1873 (Golgi, 1873). This technique introduces silver precipitate into the sample 
which then appear black in brightfield due to the high light absorption. By highlighting only 
specific parts, the composition of the sample could be investigated more accurately.  
Ramón y Cajal used Golgi’s method that had been around for several years and adapted the staining 
procedure according to the sample (Ramón y Cajal, 1917). This allowed him to draw his 
observations in extensive detail. His sketches of Purkinje cells, in particular, are famous. His 
findings contributed majorly to the knowledge about neuron structure and the cell as elementary 
component of complex organisms. Ramón y Cajal’s findings are a valuable example of how an 
established method can be improved to obtain new data.  
Based on the same principle of restricting the detection to specific parts of the sample, fluorescence 
microscopy became a milestone in the microscopy field. Instead of white light, which consists of a 
mixture of light with different wavelengths, fluorescence microscopy uses only parts of the 
spectrum. This light is absorbed by a fluorescent dye and light with less energy, i.e. at a longer 
wavelength, is emitted and detected. This results in the maximum contrast by limiting the signal to 
the location of the staining, while the rest of the sample remains mostly undetected. Another 
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advantage of using light from only parts of the spectrum is the improvement of the optical 
resolution. In 1873, Ernst Abbe published an equation describing the resolution limit of 
microscopes in relation to the wavelength of light used or light detected, respectively (Equation I; 
Abbe, 1873). Using only a narrow part of the spectrum therefore reduces the blurriness due to 
diffraction and increasesb the resolution of the system. 
  
(I) Equation | Abbe’s equation of diffraction limit. This equation describes the theoretical 
resolution limit of optical systems, where λ is the wavelength of light passing through the 
lens, n is the refractive index of the medium the light is traveling through, and θ is the angle 
the light is entering the lens with.  
Fluorescence microscopy requires specific staining methods to introduce the fluorescent dye into 
the sample. This can be achieved, similar to the silver staining, based on the biophysical properties 
like hydrophobicity. Another approach would be to label proteins of interest specifically with so-
called affinity probes. Affinity probes are molecules that specifically bind to another target 
molecules non-covalently to enable their detection. The most common technique of the latter 
approach is immunostaining, which uses fluorescently labeled antibodies.  
Confocal microscopes show an even higher resolution based on the same principle to reduce the 
signal to a very defined and restricted area. A confocal microscope is a fluorescence microscope 
illuminating only small parts of the sample at a given time. Additionally, it contains a diaphragm, 
the so-called pinhole, that excludes light from outside the focal plane (z-plane). The improved 
resolution of confocal microscopes has been used to investigate what cells are comprised of and 
how the cell functions. Therefore, it is understandable that increased resolution offers a more 
accurate representation of the cell.  
The electron microscope achieves even higher resolutions by substituting light with electrons. The 
beam of electrons has a shorter wavelength than UV light, within the picometer range (Erni, 2009). 
However, using electrons requires preparation of the sample under harsh conditions. This procedure 
is laborious, requires fixation of the sample, and is prone to introduce artifacts (Tapia et al., 2012). 
Specific labeling of target proteins is rather difficult which makes - despite the inferior resolution - 





1.2. A recent milestone in fluorescent microscopy: nanoscopy 
During the past decades, innovations in the field of fluorescence microscopy have managed to 
circumvent Abbe’s diffraction limit. The field of nanoscopy, also named super-resolution 
microscopy, emerged. The Nobel prize for Chemistry was recently awarded to two of those novel 
techniques: first, stimulated emission depletion (STED) microscopy by Stefan W. Hell. It reduces 
the signal to a confined area by application of Albert Einstein’s eponymous theory of stimulated 
depletion (Willig et al., 2006). The principle of stimulated depletion uses photons to stimulate 
excited electrons of the illuminated fluorophores to fall back to ground state. This results in light 
emission with the same wavelength as the photons used for de-excitation which can be excluded 
from detection by filters (Einstein, 1916). This so-called STED effect is applied to the periphery of 
the diffraction limited fluorescent spot (Figure 1, blue) by superimposing a second, donut-shaped 
laser beam (red). This allows the detection of only the center of the excited spot, where the power of 
the STED beam is close to zero (yellow) since the STED laser de-excites fluorophores in relation to 
its power. The lasers scan, i.e. are moved across the sample, to create the image.  
 
(1) Figure | Schematic overview of the functionality of STED. The sample is excited by a 
laser (cyan) like in a conventional laser scanning microscope. It is followed by a slightly 
delayed second laser (red) modulated to the shape of a toroid for de-exciting the 
previously excited fluorophores. Only the fluorophores in the center of the toroid, where 
the laser intensity is close to zero, will emit light and thereby creating a subdiffractional 
spot (yellow).  
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Higher intensities correlate with more de-excitation resulting in a smaller focal spot and higher 
resolution, making STED theoretically not limited to a physical barrier (Equation II). STED 
microscopy has been used on samples which require high spatial resolution, such as investigation of 
densely labeled protein clusters in the plasma membrane (Hoopmann et al. 2010; Opazo et al 2010; 
Sieber et al 2007). 
 
(II) Equation | Lateral resolution of STED microscopy. This equation describes the theoretical 
resolution limit of optical systems, where λ is the wavelength of light, n is the refractive 
index of the medium, θ is the angle the light is entering with, I is the focal intensity, and Isat 
is the saturation intensity, which describes the value at which the fluorescence is reduced to 
half. Since λ, n, and θ are constants, the lateral resolution is only determined by I/Isat and 
therefore independent of diffraction.  
The second super-resolution principle credited by the 2014 chemistry Nobel prize concerns the 
detection of the fluorophores in a temporally separated manner rather than in a spatial configuration 
(Betzig, 2006, Moerner, 2006). Stochastic optical reconstruction microscopy (STORM) exploits the 
inherent blinking nature of the fluorophores, i.e. fluorescence emission is a stochastic event, while 
photo-activated localization microscopy (PALM) uses light to switch photo-activatable 
fluorophores on and off. This allows image acquisition of fluorophore subpopulations at a given 
time. The diffraction limited spots are likely to be separated further than the diffraction limit and 
can therefore be located with high precision. A series of images is then used to reconstruct an 
diffraction unlimited image (reviewed in Toomre and Bewersdorf, 2010). The advantage of 
PALM/STORM is the simple set up. Both techniques are based on epifluorescence/TIRF 
microscopes and can be used with a variety of fluorescent dyes. On the other hand, using chip-based 
detection systems requires a high labeling density due to the inferior sensitivity compared to 
photon-counting systems, like photo multiplier tubes (PMTs) or avalanche photo diodes (APDs) 
commonly used for STED microscopy.  
1.3. Nanoscopy in molecular biology: RNA research 
A prominent example of densely labeled structures, where super-resolution is needed, are RNAs. 
The importance of RNA spikes upon the identification of new RNA species with unidentified 
function. In the 1950-60s, an intermediate between DNA and protein has been identified, the 
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messenger RNA (mRNA) (Jacob, 1961). Around the same time, it was found that ribosomes 
contain RNA as essential component for translation, which in turn is a process relying on another 
type of RNA: transfer RNA (tRNA) (Hoagland, 1956). tRNAs are triplets of RNA nucleotides 
encoding for the different amino acids.  
Since the 1990s, several RNA species where identified that do not code for proteins, summarized as 
non-coding RNAs. One representative are miRNAs, short RNA sequences that regulate protein 
expression post-transcriptionally (Bartel, 2004). Some miRNAs have been associated with diseases 
(e.g. Lewis and Steel, 2010), other non-coding RNAs have been discovered recently but their 
function is still unknown (long non-coding RNAs, lncRNAs; circular RNAs, ciRNAs) (Kapranov et 
al., 2007, Ebbesen et al., 2015).  
Biochemical and PCR-based methods (including sequencing) provide information about their 
biochemical properties and sequence but are rather limited concerning identification of function. 
The above mentioned approaches have the disadvantage requiring destruction of the cell. However, 
the location of the investigated molecule within the intact cell can provide valuable information 
about its function. Therefore, an imaging based technique for the investigation of RNAs would be 
desirable. In situ hybridization (ISH) is a method that visualizes nucleic acids (DNA or RNA) by 
exploiting their intrinsic hybridization properties of the base pairing (guanine:cytosine, 
adenine:thymine, and adenine:uracil). Labeled DNA or RNA sequences (probes) that are reverse 
complementary to the target sequence are introduced into the cell. These probes act as affinity 
probes and hybridize specifically to the target sequence and can then be detected directly or 
indirectly. The label can be detected directly if it contains a fluorophore (fluorescent in situ 
hybridization, FISH) or indirectly, which detection requires additional steps like immunostaining 
(Figure 2), thereby increasing the spot size. Many mRNAs are expressed abundantly in the cytosol, 
i.e. show a high labeling density. This makes identification of individual RNA molecules difficult, 
which is exacerbated by diffraction limited imaging techniques. In theory, a FISH protocol using 




(2) Figure | Principle of ISH. (A) RNA probes (cyan) are produced in vitro with randomly 
inserted labeled nucleotides, e.g. digoxigenin (DIG, green). The label is detected by 
enzyme-linked antibodies (yellow) which catalyze a reaction to form a colored precipitate. 
(B) Multiple synthetical DNA probes (cyan) with a defined number of fluorophores at a 
defined location within the probe (red) can be detected by fluorescence microscopy. 
1.4. Nanoscopy in medicine: AD research 
[For text related to the medical part of this work, I may refer to Aβ peptides as proteins for 
readability, especially in conjunction with tau protein.] 
Increased resolution is not only required for investigations of densely labeled samples but also when 
the size of the target of interest is relevant. One example in the field of medicine would be protein 
aggregates observed in Alzheimer’s disease (AD).  
AD is the most common form of dementia and was first described by Alois Alzheimer in 1907 as a 
“peculiar disease of the cerebral cortex” (Alzheimer, 1907). The reported female patient showed 
severe memory deficits and disorientation, while her motor ability remained normal. After her 
death, the autopsy revealed abnormal intracellular fibrils and macroscopic plaques in the cortex. 
Alzheimer made those neurofibrillary tangles and amyloid plaques, which became the 
neuropathological hallmarks of AD, responsible for the degeneration of neurons.  
This correlation was established more than 60 years later upon the work of Blessed, Tomlinson, and 
Roth (Blessed, 1968). The authors investigated post-mortem brain samples with respect to the 
patients’ cognitive capabilities before death. They found that the number plaques correlates with 
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dementia severity. Another 15 years later, it was found that those amyloid fibrils and neurofibrillary 
tangles consist mainly of β-amyloid (Aβ) and hyperphosphorylated tau, respectively (Glenner and 
Wong, 1984, Dickson, 1992, Morris et al., 2011).  
The amyloid precursor protein (APP) is a transmembrane protein (Figure 3). It has been related to 
several functions, including synapse formation and function (Priller et al., 2006), neural plasticity 
(Turner et al., 2003), and iron metabolism (Duce et al., 2010). Mutations of APP have been 
associated with abnormally elevated levels of its cleavage product Aβ causing familial cases of AD 
(e.g. Scheuner et al., 1996). Aβ is released to the extracellular space upon two successive cleavages 
of β- (orange) and γ-secretase (green), where it aggregates to oligomers and eventually insoluble 
fibrils (lower part). APP can also be processed by a non-amyloidogenic pathway, where α-secretase 
(red) cleaves APP within the Aβ sequence (dashed box). However, the functions of both APP and 
its cleavage products are still unclear and under active investigation.  
 
(3) Figure | Proteolytic processing of APP and formation of plaques. The transmembrane 
protein APP can be processed in two ways: 1) In the non-amyloidogenic pathway (dashed 
box): α-secretase (red) cleaves APP within the Aβ sequence (cyan) which prevents release 
of Aβ upon subsequent cleavage of γ-secretase (green). 2) The amyloidogenic pathway: if 
APP is processed by β-secretase (orange) prior to γ-secretase, Aβ is released into the 
extracellular space and can form oligomers and fibrils.  
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However, even after more than a century of research, it is still under debate if those macroscopic 
assemblies, i.e. amyloid plaques and neurofibrillary tangles, are indeed causing neurotoxicity in 
AD. There are several reports of patients with AD symptoms but no plaques or tangles, as well as 
individuals with plaques or tangles but no signs of dementia (e.g. Terry et al., 1991). But it has been 
rather well established that Aβ and tau play a central role in AD pathology. This led to the 
hypothesis that smaller, soluble assemblies may be the actual toxic forms rather than large, 
insoluble ones (Viola and Klein, 2015). It is thought that formation of those aggregates may even be 
a cellular response to counteract the neurotoxicity by sequestering the toxic oligomers in those 
insoluble deposits. Various studies used a range of techniques trying to identify the toxic species. 
Different synthetic Aβ species have been investigated in vitro or applied to various cell and animal 
models to mimic the disease with varying results (Motter, 1995, Georganopoulou et al., 2005, 
Esparza et al., 2013, Savage et al., 2014).  
1.4.1. Current state of AD diagnosis 
Autopsy is currently still the definite determination of AD. Pre-mortem, the diagnosis of AD is still 
mainly based on cognitive tests which are performed oftentimes over years and require experienced 
neurologists (McKhann et al., 2011). Therefore, an alternative diagnosis method is actively 
searched for that relies on lab results. Currently, the most promising lab-based diagnosis method 
relies on enzyme-linked immunosorbent assay (ELISA). The protein of interest, Aβ and tau are 
most commonly used, is immobilized and its concentration is measured using enzyme-linked 
antibodies. Those enzymes catalyze a chemical reaction that emits light (bioluminescence), which is 
used to extrapolate the amount of antibodies and therefore the amount of the protein of interest.  
Due to their easy accessibility, serum and blood have been used as sample. However, the results are 
inconclusive (Mayeux et al., 2003, Irizarry, 2004, van Oijen et al., 2006), therefore making cerebral 
spinal fluid (CSF) the sample of choice. CSF surrounds the central nervous system where it 
mediates the exchange of metabolites between the central nervous system and the blood circulatory 
system. Since amyloid plaques are found extracellularly, there is a high chance that the composition 
of CSF reflects the situation in the brain and therefore can be used as a way to monitor AD 
development and progression. 
Despite promising studies of ELISA using CSF, their results are still under debate (McKhann et al., 
2011, Zetterberg and Blennow, 2013). An assay that relies not only on total protein concentrations 
but also factors in assembly size and structure (i.e. fibrillar, spherical, etc.) should be more precise 
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and thus more promising for a new diagnosis method (Fukumoto et al., 2010). In theory, imaging 
immunostained CSF at high resolution should be able to provide this type of data.  
1.5. Scope of this work 
In this study, I optimized established staining methods in the fields of molecular biology and 
medical diagnosis for STED microscopy, i.e. fluorescent in situ hybridization (FISH) and 
immunostaining, respectively. Regarding the former, STED-FISH may shed new light on past 
issues or provide valuable information on current ones, e.g. on the recently identified circular RNAs 
(ciRNAs) to help unveiling their function. Imaging methods like FISH may identify or at least 
exclude functions due to (co-)localization data. Due to the high density of RNAs within cells, the 
resolution of conventional light microscopy is not sufficient to obtain accurate information about 
the organization of RNAs. Therefore, I optimized a FISH protocol for STED microscopy to 
contribute to the investigation of the molecular mechanisms of mRNA distribution and dynamics 
within cells.   
Concerning the field of medical diagnosis, super-resolution - based techniques may contribute to the 
research on aggregopathies like Alzheimer’s disease (AD). Despite decades of research, neither is 
the exact cause known, nor does a successful therapy exist. The two candidate proteins Aβ and tau 
have been used as biomarker to develop a diagnosis method, mostly based on ELISA with varying 
results. There is a need for a reliable, lab-based diagnosis method which, ideally, fulfill all these 
features: 1) it should be lab-based, i.e. independent from the person doing the experiment; and yield 
immediate results unlike cognitive tests which may take several years. 2) it should also be able to 
monitor disease severity since different disease stages might require different treatment. 3) It should 
be able to predict the disease at prodromal stages, where the patients are still symptom free. Based 
on those requirements, I approached this problem from a more direct angle. Instead of relying on 
assays which only determine the concentrations or use rather harsh conditions to investigate those 
fragile assemblies, I wanted to monitor Aβ and tau particles directly. In principle, this should be 
feasible by immunostaining and fluorescence microscopy. However, those assemblies are smaller 
than the diffraction limit of conventional (confocal) light microscopy (~200 nm). This is why I 
turned to STED microscopy, which has a resolution limit of ~50 nm at our microscope. I tried to 
develop a diagnosis method using super-resolution imaging data of immunostained Aβ and tau in 
CSF. The STED parameters spot size, spot number, spot intensity, total fluorescence intensity 
should, in principle, reflect dimensions of the particles, number of particles, how many Aβ or tau 
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molecules per particle, and overall protein concentration, respectively. These features then can be 






2.1. Establishing a FISH protocol for STED microscopy 
Super-resolution microscopy has been mostly applied to studies of protein organization with regard 
to biological samples. Not only the number of studies identifying new RNA species but also their 
role in regulating protein expression has been increasing. However, those studies mostly relied on 
sequencing or biochemical assays. In this work, I refined the fluorescent in situ hybridization 
(FISH) protocol for STED microscopy I established during my Master’s thesis (Zhang, 2011). This 
does not only allow to localize RNAs but also to monitor their intermolecular organization.  
For this approach, I chose to use fluorescently labeled DNA oligonucleotides as probes for the 
following reasons: 1) DNA probes are easier to handle due to widespread presence of RNases, 
thereby reducing the risk of degradation of the probes and signal loss. 2) Short probes penetrate 
cells and tissue easier than long ones. 3) Short probes also enable the use of multiple different 
probes per target RNA to increase the signal-to-noise ratio. 4) Since the probes are chemically 
synthesized, the probes have a defined number of fluorophores at defined positions rather than 
random incorporation of labeled nucleotides during in vitro transcription. 
2.1.1. STED-FISH stains mRNAs specifically 
To check whether the FISH staining was specific, two control experiments were performed. First, 
cells that do not express the three synaptic proteins synaptophysin, synaptobrevin, and 
synaptotagmin endogenously were transfected to express the synaptic proteins and stained by FISH. 
Second, the same mRNAs of the three synaptic proteins were stained by FISH by three different 
probes, this time not covering the coding sequences (CDSs) but the untranslated regions (UTRs). 
Regarding the first control experiment, the transfected cells can be easily identified because they 
express the synaptic protein fused to a GFP derivate called pHlourin (Figure 4, green). FISH signal 
could be observed in transfected cells only (Figure 4 B, red). Little signal could be detected in 
transfected cells using the control probes. The control probes were sense sequences of the target 
mRNA which was able to detect the double stranded plasmids (Figure 4 A). Untransfected cells 




(4) Figure | Cos-7 cells transiently transfected with fusion versions of synaptic proteins. 
Transfected cells can be easily identified by the GFP signal (green), while untransfected 
cells are revealed by DAPI staining (blue). (A) Only little signal can be observed within 
transfected cells when using the control probes (red). The signal originates from specific 
annealing of the probes to the plasmids that contain both sense and anti-sense sequences 
of the respective genes. (B) Only transfected cells contain high FISH signal (red). These 
epifluorescence images were scaled identically for each channel. Scale bars, 10 µm. 
As the other control, I performed FISH to detect the transcripts but this time using a different set of 
probes against the UTRs of the mRNAs of the three synaptic proteins and compared the staining 
results of the two sets of probes. The spot densities of both sets were not statistically different from 




(5) Figure | Comparison of spot densities between probes targeting the UTRs and CDSs. No 
statistically significant difference could be seen for any of the mRNAs of the three 
synaptic proteins (n = 5 to 6), suggesting that a representative population was detected. 
2.1.2. Three probes per RNA target are sufficient for reliable detection 
True signal can be discriminated from unspecific binding by fluorescence intensity (Figure 4). 
Using only one probe was not sufficient to differentiate signal (grey) from background (black). This 
especially applies for RNAs expressed at low levels, where background might mask the true signal. 
In contrast, performing FISH with three different probes per RNA target increased the fluorescence 
intensity per spot significantly allowing reliable identification of the mRNAs (cyan). 
  
(6) Figure | Histogram of spot intensities with regard to number of probes used. Using only 
one probe (grey) was not sufficient to reliably distinguish from controls (black). If three 
probes were used (cyan), the intensity of the majority of the spots was significantly 
higher than the controls (p<0.001; t-test). 
Since the protocol should be universal for all RNAs (except for very short ones like miRNAs), I 
decided to use only three probes per RNA. The probes must not overlap to compete for binding 
sites, nor have cross-reactivity with each other or other transcripts of the sample. This may already 
be difficult, especially for short RNAs. In the case of synaptobrevin, the three chosen probes were 
the only possible ones. All probes should be of the same physical properties, so that the 
hybridization conditions are similar for all probes, i.e length and melting temperature (Tm). If 
mature mRNAs are of interest, the selection criteria are even more strict as the probes should span 
over adjacent exons. 
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2.1.3. STED-FISH provides information about RNA organization 
I then stained endogenous levels of mRNA of the three synaptic proteins synaptophysin, 
synaptobrevin, and synaptotagmin in primary hippocampal neurons. Figure 7 shows a neuron 
identified by synaptophysin immunostaining (cyan). Most of the FISH signal (red) was localized in 
the cytoplasm of the neuron. Comparison of the confocal and STED images reveal that some of the 
diffraction limited spots actually consist of multiple spots (cyan circles). This indicates higher 
numbers of mRNA molecules than apparent in confocal images, making STED more accurate.  
 
(7) Figure | STED provides more accurate information than confocal microscopy. Confocal 
and STED images of a neuron stained by immunofluorescence (cyan) and FISH (red) 
against synaptophysin protein and mRNA. Looking at the zoom-ins (white square), some 
of the diffraction limited spots in the confocal image consist of multiple spots revealed by 
STED (cyan circles). Scale bars, 5 µm (for overview of neuron) or 1 µm (for zoom-ins).  
The increased resolution with STED-FISH did not only allow a more precise estimation of the 
mRNA numbers but also provided information about the intermolecular organization. The spots of 
the three synaptic proteins were approximately ~50-60 nm in size, i.e. at the resolution limit of the 
STED microscope used for this work (Figure 8, first three panels). In contrast, the spots of β-actin 
mRNA were noticeably larger and brighter (~80 nm, right panel), suggesting an organization in 




(8) Figure | STED-FISH is able to resolve mRNA organization. STED images of neurons 
stained by FISH against the mRNAs of synaptophysin, synaptobrevin, synaptotagmin, and 
β-actin (upper panel) and the respective line scans (white lines in the images, graphs in the 
lower panel). While the spot sizes of the three synaptic proteins was close to the 
resolution limit of our microscope (~50-60 nm; first three columns), β-actin showed larger 
spots (~80 nm; fourth column). Also note the scaling of the y-axis, showing 
approximately double the fluorescence intensity for β-actin. Scale bar, 1 µm. 
2.1.4. STED-FISH is able to monitor mRNA levels qualitatively 
FISH can monitor RNA levels qualitatively based on the spot number in relation to the volume of 
the cell. This type of quantification may not be as accurate as biochemical assays like quantitative 
PCR (qPCR). Those methods, however, usually require more material (i.e. cells). mRNA levels of 
the three synaptic proteins and of the general housekeeping protein β-actin were investigated with 
regard to neuronal development in vitro. The mRNAs, as measured by spot density, of all four 
proteins increased with maturation (Figure 9; cyan, red, green, and yellow), while the spot density 
of the control probes remained at the baseline (black). Interestingly, synaptophysin showed the 




(9) Figure | Changes in mRNA levels with respect to age in vitro. The numbers of mRNA 
molecules for β-actin and the three synaptic proteins increase with age while the control 
stayed on the baseline level. Interestingly, the spot density of Syp FISH (red) increased 5-
fold until DIV 20 and decreased to the 4-fold of the initial level at DIV 28.  
2.2. Establishing a microscopy-based diagnosis method for AD 
Despite Alzheimer’s disease (AD) being the most common form of dementia, its diagnosis mainly 
relies on cognitive tests. This means that the patients already show symptoms of cognitive 
impairment at the time of diagnosis, due to potential neuronal damage possibly caused by abnormal 
Aβ and/or tau assemblies (Andreasen and Blennow, 2005). Therefore, I turned to STED microscopy 
analyzing Aβ and tau assembly numbers and sizes in human CSF to develop a novel diagnosis 
method. Compared to only analyzing their concentrations in CSF or the cognitive states of the 
patients, my approach might 1) diagnose the disease more reliably and with higher accuracy. STED 
is able to additionally provide information about particle size and organization, which is thought to 
be a major factor of the neuronal toxicity (oligomers vs insoluble fibrils, also see Section 1.4); 2) 
detect the disease at prodromal stages when toxic Aβ and tau species have formed but have not 
affected the patients cognition; and 3) monitor disease severity and thus disease progression. 
To characterize Aβ and tau assemblies, I analyzed human CSF samples of 36 AD patients, 21 
controls, and 11 mild cognitive impaired (MCIs). The underlying idea was to immobilize CSF on 
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coverslips, immunostain for Aβ and tau, and to analyze their assembly characteristics by STED 
imaging (Figure 10). 
 
(10) Figure | Schematic overview of the experimental procedure. PLL coated coverslips were 
incubated with CSF. The samples were then fixed and immunostained using primary 
antibodies and secondary Fab fragments conjugated to Atto647N. The images obtained by 
STED imaging were analyzed by a custom-written MatLab macro.  
2.2.1. Optimization of coverslip coating and fixation 
The first challenge was to immobilize the proteins present in the CSF on coverslips for 
immunostaining. This procedure needs to fulfill several criteria: 1) The proteins need to be 
immobilized on the coverslip to endure the immunostaining procedure. 2) The procedure should 
represent the CSF in protein composition and organization. Especially in the case for Aβ, it is 
known that even at room temperature aggregates may form (Zimmermann et al., 2011).  Therefore, 
the fixation should be as short as possible to avoid artifacts. 3) It should not interfere with the 
antibody recognition. Some fixatives like glutaraldehyde are known to change the epitopes so that 
antibodies cannot bind to their targets (Shtengel et al., 2014). I tested four coating agents and four 
fixation solutions for the best immunostaining result. The combination of PLL coating and 4% PFA 
fixation (Figure 11, cyan square) achieved the most signal, implying that most material was fixed to 
PLL by 4% PFA only and that the fixation procedure did not interfere with the antibody 




(11) Figure | Epifluorescence images of coating and fixation optimization. I tested four 
conditions each for coating (PBS, PLL, BSA, or peptone) for a suitable substrate and for 
fixation (no fixative, PFA, PFA and glutaraldehyde, or glutaraldehyde) to immobilize the 
CSF onto the coverslips. The combination of PLL coating and fixation with 4% PFA 
yielded the most immunofluorescence (cyan square). Colors inverted for better visibility. 







2.2.2. Antibody selection and blocking 
As for all immunostainings, the staining conditions need to be optimized for each antibody and 
sample type. Different antibodies bind to different epitopes with different affinities, which in turn 
affects the level of blocking needed to avoid poor signal-to-noise ratio or even artifacts. This is 
especially critical for immunostaining CSF since there are no structures for orientation as for cells 
or tissue samples. I tested nine different antibodies against different Aβ species, since the toxic Aβ 
isoform is still under debate; four against different tau versions, some of them against 
phosphorylated forms, since neurofibrillary tangles have been found to contain 
hyperphosphorylated tau proteins; as well as two oligomer-specific antibodies to detect only the 
potentially toxic species (see Section 4.4 for complete antibody list).  
Blocking solutions for antibody stainings typically contain proteins that do not interfere with the 
antibody recognition to compete with the antibodies for any unspecific binding. Different blocking 
solutions with different blocking agents at varying amounts of protein were tested for each 
antibody. To test the background, only coverslips incubated with BSA instead of CSF were used 
(negative control), since it should be free of epitopes and therefore show only little signal. Figure 12 
shows the blocking optimization for a selection of four antibodies. The 6E10 and the pan tau 
antibody are thought to detect all forms of Aβ and tau, respectively, while ab10148 and ab12267 
were reported to only recognize specific Aβ species (see Section 4.4 for details).  
Similarly to numerous other previous studies on Aβ in human CSF (e.g. Pirttilä et al., 1994, 
Maddalena et al., 2004), 6E10 was selected for the investigation due to its high sensitivity. Its 
property to potentially detect all Aβ species might allow the acquisition of a more complete protein 
profile of the CSF. Similarly, I chose the pan tau antibody for investigation of the tau CSF contents. 




(12) Figure | Epifluorescence images of the optimization of blocking conditions. Coverslips 
were incubated with BSA only instead of CSF (negative control) and immunostained as 
described in Methods using different blocking solutions. Using the strongest blocking (5% 
BSA plus 5% peptone) obtained the fewest unspecific staining and was therefore used for 
all experiments. All images were scaled identically. Images were inverted in color to 
provide better visual representation. Scale bar, 2.5 µm. 
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2.2.3. Super-resolution is able to separate assemblies of different sizes   
Confocal images of CSF immunostained against Aβ showed many spots with many of them 
touching or overlapping each other. Imaging the same samples with STED provides more accurate 
information due to the increased resolution. Similar to STED-FISH (Figure 7), some diffraction 
limited spots in the confocal images actually consisted of multiple individual spots which offered 
more precise numbers of Aβ assemblies (Figure 13 A, red circles). In addition, a line scan over the 
same representative spot imaged in confocal and STED mode (cyan circle) showed the resolution 
limits of both techniques (~277 nm for confocal and ~45 nm for STED, Figure 13 B). The higher 
resolution of STED may help to identify the size of the toxic species.  
 
(13) Figure | Comparison of immunostained CSF imaged by confocal and STED microscopy. 
(A) CSF was immunostained as described in Methods and imaged in confocal (left) and 
STED (right) mode. The increased resolution of STED offers more details about the 
composition of Aβ assemblies in the CSF. With confocal, all three spots highlighted by 
the red circles can only be identified as one spot. In contrast, STED is able to resolve them 
originating from multiple or one single, bright object. (B) Raw (cyan) and fitted (black) 
line scans of the same individual spot (cyan circles in panel A). Confocal microscopy is 
limited by diffraction and thus is only able to resolve object to ~ 250 nm (full width of 
half maximum, FWHM) while STED can differentiate spots which are ~ 25 times smaller 
(FWHM of ~ 50 nm in both x- and y-dimension). Scale bar, 1 µm. 
Next, to test whether STED is indeed capable of discriminating assemblies of different sizes, I 
immunostained low- (LMW) and high-molecular weight (HMW) assemblies of in vitro synthesized 
Aβ peptides. LMW Aβ showed small spots of similar sizes, while HMW Aβ showed spots of 
different sizes with many remarkably larger than for LMW Aβ (Figure 14 A). Analysis of the 
STED images showed a clear difference between the two samples (Figure 14 B). LMW Aβ spots 
were smaller and dimmer (indicating fewer Aβ molecules per spot) than HMW Aβ spots. Assembly 





(14) Figure | STED assessment of low (LMW) and high molecular weight (HMW) Aβ 
assemblies produced in vitro. (A) Representative STED images of synthetically produced 
LMW (left) and HMW Aβ assemblies (right). Colors were inverted for better visibility. 
Scale bar, 1 µm. (B) The quantification shows that the two Aβ species can be 
discriminated from each other by either spot size or intensity. Note that the mean spot size 
of the LMW assemblies is close to the resolution limit of the microscope. Graph shows 
means ± SEM.  
These results show that I successfully established an immunostaining protocol for Aβ and tau of 
human CSF for STED microscopy capable of discriminating assemblies of different sizes.  
2.2.4. AD patients show fewer, smaller, and dimmer spots than controls 
CSF samples from 36 AD patients, 21 controls, and 11 MCI were immunostained for Aβ and tau, 
imaged by STED, and analyzed as described in Methods. Figure 15 A shows representative STED 
images of CSF samples from controls (upper panel) and AD patients (lower panel) immunostained 
for Aβ. Intriguingly, AD patients showed fewer, smaller, and dimmer spots (Figure 15 B). This may 
be accounted by sequestration of Aβ peptides into amyloid plaques in the brain, thereby reducing 




(15) Figure | Analysis of CSF Aβ by STED imaging. (A) Example STED images of CSF 
immunostained for Aβ. AD patients (lower panel) show smaller and fewer spots than 
controls (upper panel). Images were color inverted for better visibility. Scale bar, 1 µm. 
(B) Bar graph of the mean values of the four STED parameters (spot size, spot intensity, 
spot density, and average intensity) and Aβ concentration determined by ELISA. Controls 
show statistically significant higher values than AD patients for each parameter (* < 0.05; 
*** < 0.001).  
2.2.5. STED parameters of tau increased prediction accuracy  
With the means of all four parameters (spot size, spot intensity, spot density and overall intensity) 
being significantly different in AD patients and controls (Figure 15 B), I analyzed CSF samples 
with regard to tau (Figure 16). Despite none of the STED parameters being significantly different 
between AD patients and controls (Figure 16 B), combination of Aβ and tau data increased 
prediction accuracy from approximately 76% for both sensitivity and specificity to 79% and 87%, 
respectively (Figure 16 C-E), with sensitivity defined as the percentage of AD patients that were 
correctly identified and specificity defined as the percentage of controls that were correctly 
identified. The underlying discriminator functions F(Aβ) and F(Aβ, tau) were obtained by 
combining all four parameters in a linear equation (Equation III and IV). Finally, the STED values 




(16) Figure | Analysis of CSF tau by STED imaging and prediction accuracy of STED. 
(A) Representative STED images of CSF immunostained for tau. AD patients tend to 
show more spots. Images were color inverted for better visibility. Scale bar, 1 µm. (B) Bar 
graph of the mean values of the four STED parameters (spot size, spot intensity, spot 
density, and average intensity). Differences in neither of the four parameters were 
statistically significant (n.s.) (C) Prediction accuracy of the STED-based assay according 
to the cut-off for the F(Aβ) value or (D) F(Aβ, tau) value (dashed lines). (E) Improved 





(III) Equation | Discriminator function using STED parameters from Aβ data. This equation 
assigns a value to each patient according to the STED parameters for Aβ, where a and b are 
constants and b surpasses a by 3-4 fold. Best separation of AD and controls was achieved 
with a cut-off value of ~3.7. 
 
(IV) Equation | Discriminator function using STED parameters from Aβ and tau data. This 
equation assigns a value to each patient according to the STED parameters for Aβ and tau, 
where a and b are constants and both left at 1. Best separation of AD and controls was 
achieved with a cut-off value of ~1.7. 
 
(17) Figure | Comparison of STED and ELISA prediction accuracies. (A) F(Aβ) values and (B) 
F(Aβ, tau) values are plotted on the X-axis against Aβ concentrations determined by 
ELISA on the Y-axis; controls are displayed in black, AD patients in cyan. The dotted 
lines indicate the cut-off values used to separate AD patients from controls at 450 pg/ml 
for ELISA and 3.77 for F(Aβ) or 1.70 for F(Aβ, tau), respectively. The four regions within 
 
 40 
the graphs represent: (1) patients identified as controls by both ELISA and STED; (2) 
patients identified as AD by both techniques; (3) patients identified as controls by ELISA 
but as AD by STED; (4) patients identified as AD by ELISA but as controls by STED. It 
is evident that most patients fall into the areas (1) and (2) indicating identical prediction 
by both techniques for the majority of the patients. (C-D) For graphic view of 
identification accuracies, the same graphs are displayed color-coded as indicated in the 
legend. The green dots dominate indicating that both techniques identified most of the 
patients correctly.  
2.2.6. STED parameters of two MCI patients were within AD range 
The same method was applied to patients with mild cognitive impairment (MCI, see Section 4.8.3.). 
Two of the MCI patients developed full AD during the course of the study and were placed close to 
the AD average of the STED assay (Figure 18). This indicates that STED might have the capability 
to predict AD at prodromal stages.  
 
(18) Figure | STED values of MCI patients with respect to the averages of AD patients (grey) 
and controls (black). MCI patients are indicated by red dots, with the two MCIs that 
converted to full AD during the study which are depicted in green. Note that the green 




In this work, I have applied STED microscopy - as a representative for super-resolution microscopy 
techniques - to two applications: fluorescent in situ hybridization (Section 2.1) and diagnosis of 
Alzheimer’s disease (Section 2.2). Due to the increased resolution of STED, the methodologies 
needed to be optimized for the needs. This works shows that using STED with well established 
methods provides more accurate information compared to conventional confocal microscopy. For 
both cases, STED was able to reveal multiple spots per individual diffraction limited spot. This 
allowed to characterize mRNA levels and organization of the synaptic proteins synaptophysin, 
synaptobrevin, and synaptotagmin and the housekeeping protein β-actin more accurately than by 
conventional light microscopy (Section 2.1.3.). β-actin mRNA seems to be organized in units of 
multiple RNA molecules as those particles were larger and brighter compared to the spots of the 
synaptic proteins (Figure 8). 
This first application of super-resolution microscopy to medical diagnosis was able to discriminate 
controls from AD patients by analyzing images of immunostained CSF samples. The assay uses the 
parameters number and size of assemblies and number of Aβ or tau molecules per assembly, which 
allowed a separation with a specificity of ~87% and a sensitivity of 79% (Figure 16). This accuracy 
is comparable to the one achieved by ELISA, the current gold standard in the field. In addition, two 
of the MCIs who converted to full AD during the study showed similar Aβ profiles as AD patients 
(Figure 18). Despite being only a very small sample size, these side findings encourage for further 
investigations. 
3.1. Technical limitations 
Both applications posed a particular challenge compared to other targets or sample types, like 
organelle marker or cell culture systems. In both cases in this study, the stainings were difficult to 
be confirmed by structure, since the images consisted of seemingly random spots. For staining and 
imaging CSF, there is only a single layer of molecules to be imaged, which adds to the difficulty. 
Due to the low amount of material, there is only little fluorescence in the first place, thereby 
decreasing the signal-to-noise ratio and resolution. In addition, drifting might cause not only 




3.2. Technical limitations of FISH 
3.2.1. Loss of RNA 
Another issue is the loss of RNAs during the experimental procedure. For one, contaminations with 
widespread present RNases may degrade a large percentage of RNAs, including the target mRNA 
and thereby reducing the FISH signal. Second, the fixative PFA fixes cells mainly based on cross-
linking proteins. Due to repeated washings under harsh conditions (i.e. formamide and temperatures 
well above room temperature) non-proteinaceous molecules like RNAs may be lost and can 
therefore not be detected by FISH. The issue of signal loss can be exacerbated by masking of the 
binding sites for the probes on the mRNA molecules by translating ribosomes or other RNA-
binding proteins. 
3.2.2. Inefficient blocking  
Many blocking solutions for in situ hybridization protocols include sheared Salmon sperm DNA to 
block unspecific binding of the probes. These random sequences compete with the probes with 
DNA/RNA-binding proteins, other nucleic acids, and other unspecific interactions due to the same 
nature. However, its blocking capabilities may be suboptimal due to its size. According to different 
manufacturers, the size of most DNA molecules is larger than 1000 bp, which is ~2-5x the size of in 
situ hybridization RNA probes and ~20-50x of DNA probes. The cytosol is densely filled with 
protein which are cross-linked by fixation. Considering that one nucleotide is generally larger than 
one amino acid, it seems quite plausible that many unspecific binding sites of the probes are not 
blocked by the Salmon sperm DNA because they cannot reach the binding sites the probes can due 
to their size. To alleviate this issue, I used Salmon sperm DNA that has been further processed by 
sonication to sizes around 200 bp by the lab of Andre Fisher, DZNE, Göttingen, Germany.  
3.2.3. Signal amplification 
In principle, weak signal could be amplified by increasing the number of probes per target, by 
increasing the number of fluorophores per probe, and/or by using indirect labeling. Increasing the 
number of probes per target may be difficult to achieve. Designing probes for transcripts that are 
short or contain sequences similar to others (e.g. different isoforms) might not be possible without 
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cross-reactivity. Using many probes per target sequence might increase the size of the resulting 
spot. Having too many fluorophores in close proximity may also result in auto-quenching of the 
fluorophore (Wolfbeis, 2005). Increasing the number of fluorophores per probe also increases the 
costs. There are two approaches for indirect labeling: use of antibodies and the use of enzymes. 
Using a primary-secondary or even an added tertiary antibody will amplify the signal for each tier 
since multiple secondaries can bind to a single primary antibody (similar for tertiary antibodies to 
secondaries). Using enzymes will produce signal that diffuses within the cell. Both amplification 
approaches result in a larger spot and thereby decreasing the resolution. A balance between 
sensitivity and accuracy based on resolution needs to be chosen well.  
3.3. Technical limitations - AD 
3.3.1. Limitations of the field 
A major issue in the field is that it is difficult to compare between studies. One factor is differences 
of sample acquisition. The protein levels in the CSF are dependent on the circadian rhythm. 
Therefore changes in the time of day when the lumbar puncture is performed may affect 
experimental results (Cicognola et al., 2015). Other artifacts may occur due to differences in 
processing of the CSF, i.e. speed of processing after lumbar puncture, centrifugation duration and 
properties, as well as the material of the equipment and containers used. Heterogeneity in the plastic 
composition of the equipment are known to absorb Aβ and thereby may deplete the CSF of Aβ for 
further analysis (Fourier et al., 2015). Furthermore, the way the samples are stored may also affect 
the protein composition of the CSF. Especially, thaw-freeze cycles are known to affect tau 
concentrations (Schoonenboom et al., 2005).  
Another issue is the study cohort. Suitable controls need to be included (age, ethnicity, etc). 
However, obtaining CSF from subjects with no medical condition was not possible due to the local 
ethics commission. This would allow monitoring the disease onset, which is essential to develop 
therapies. Moreover, it is hard to find a study cohort that is in general representative of the (local) 
population.  
The current diagnosis methods still relies on medical assessments, which have inaccuracies 
especially when dealing with early cases of AD. Since the development of the STED-based 
diagnosis depends on initial medical classification of the patients, the assay may not be able to 
reach full accuracy. This issue is illustrated by the fact that some patients were diagnosed 
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differently in the course of the study, since accurate identification of similar dementia forms is 
difficult (Hulstaert et al., 1999). This interfered with the analysis and the development of a 
discriminator function. This can be countered by long-term studies. Further longitudinal follow-up 
studies are needed to confirm the results of this study and especially to test its prediction accuracy 
for AD at prodromal stages. Ideally, young adults would be followed until their death. CSF samples 
of those patients could be analyzed with respect to the patients’ long-term medical history and 
autopsy data for more accurate diagnosis. 
3.4. Outlook 
The STED-based diagnosis method of AD and other aggregopathies might be remarkably improved 
by the development of new affinity probes. First, isoform- or conformation-specific affinity probes 
may refine the prediction accuracy by focusing on the toxic protein species only. Second, using 
smaller affinity probes like nanobodies or aptamers reduces the distance between the epitope and 
the fluorophore, therefore the spot size. This provides more precise information about the actual 
physical dimensions of the target, in this case Aβ and tau particles. This might allow even the 
identification of the toxic species. Future generations of microscopes and novel microscopy 
techniques with improved resolution may further increase the precision.  
Another factor that is often neglected is the influence of the dye on the staining results. The opto-
physical properties of the dye determine the image quality, like speed of bleaching or quantum 
yield. Quantum dots, for example, have a high quantum yield with low photobleaching. However, 
other factors need to be considered as well. Quantum dots are relatively large in size (5-50 nm; 
Massey et al., 2015). This would affect the diffusion properties of the affinity probe remarkably and 
thus impair tissue penetration, which is especially important when considering quantum dots for 
labeling of oligonucleotides for FISH. The size of the dye also affects the resolution of the image. 
The larger the dye, the larger the spot and thus the worse the resolution.  
Another factor to keep in mind, is the dye’s general physical property. Concerning this work, 
Atto647N, the dye that achieved the best results for this study, is highly hydrophobic (Zanetti-
Domingues et al., 2013). This may lead to unspecific binding, especially to membranes, and thus a 
suboptimal signal-to-noise ratio or even misleading artifacts. In extreme cases, it may cause the 
affinity probe to precipitate. 
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Therefore, these factors should be taken into account when doing a staining since re-optimization 
may be required. Innovations in dye development may improve the staining and imaging results in 
general and due to the possibility of co-stainings/co-localizations and coincidence detection.  
In conclusion, this work illustrates the need for optimization of even long established methods 
dependent on the imaging technique and sample type used. This allows the acquisition of detailed 
and therefore more accurate data. Both projects presented represent first steps in the fields of RNA 
and medical research encouraging follow-up or new studies and re-investigation of past questions, 
which were not able to be answered due to the lack of resolution of conventional fluorescence 
microscopy.   
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4. Material and methods 
All experiments were performed at room temperature unless otherwise stated.  
4.1. General chemicals and manufacturers 
The laboratory equipment and chemicals used in this work were purchased from the companies or 
were provided from groups of the institutions stated in the following table. For individual cases 
within the rest of the document, only the short company name will be given. Please refer to this 
table for more information.  
(A) Table | List of manufacturers and institutes. 
company / institute city, state country 
Abcam Cambridge UK 
ATTO-TEC GmbH Siegen Germany 
Covance Inc. Princeton, NJ USA 
Chroma Technology Corp. Bellow Falls, VT USA 
Dako Cytomation Glostrup Denmark 
Eppendorf Hamburg Germany 
Eurofins Scientific GmbH Hamburg Germany 
GE Healthcare Little Chalfont UK 
Gerhard Menzel GmbH Braunschweig Germany 
Gibco Paisley UK 
Instituto de Salud Carlos III Madrid Spain 
Invitrogen Carlsbad, CA USA 
Leica Microsystems GmbH Mannheim Germany 
Life Technologies Carlsbad, CA USA 
Lonza GmbH Cologne Germany 
Max-Planck-Institute for Biophysical 
Chemistry Göttingen Germany 
Max-Planck-Institute for 
Experimental Medicine Göttingen Germany 
Merck Millipore Darmstadt Germany 
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company / institute city, state country 
New England Biolabs Frankfurt am Main Germany 
Newport Spectra-Physics GmbH Darmstadt Germany 
Olympus Corporation Tokyo Japan 
PAA Laboratories GmbH Clöbe Germany 
Peptide Specialty Laboratory (PSL) Heidelberg Germany 
AJ Roboscreen GmbH Jena Germany 
Seqlab Göttingen  Germany 
Sigma Aldrich St. Louis, MO USA 
Synaptic Systems Göttingen Germany 
The Mathworks Inc.  Natick, MA USA 
Universitätsklinkum Tübingen Tübingen Germany 
University Medical Center Göttingen Germany 
 
4.2. Buffers and solutions 
Phosphate-buffered saline (PBS): 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM 
KH2PO4; pH 7.4. 
High salt PBS: 500 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 2.0 mM KH2PO4; pH 7.4 
Paraformaldehyde (PFA): 4% PFA (Merck) in PBS. Preparation: 8 g PFA was dissolved in 180 
ml de-ionized water by mixing at mild heating and addition of 200 µl 10 M NaOH. After adding 20 
ml 10x PBS, pH 7.4, the pH was adjusted to 7.4 with HCl. The solution was aliquoted and stored at 
-20ºC until the day of the experiment.  
Tris buffer: 1 M tris, adjust to pH 8.0 with HCl.  
Mowiol: 2.4 g Mowiol 4-88 (Merck), 6 g glycerol, 6 ml de-ionized water and 12 ml 0.2 M Tris 
buffer. Preparation: The chemicals were mixed up to 5 days at mild heating and adjusted to pH 8.5 






(B) Table | List of antibodies. 
target company/ 
institute 
catalogue number / clone host 








Aβ Bayer lab 167 mouse 
















Aβ Abcam ab10148 rabbit 
polyclonal 
Aβ Abcam ab12267 rabbit 
polyclonal 
APP Synaptic Systems 127002 rabbit 
tau Dako Cytomation A0024 rabbit 
p-tau Abcam ab4856 rabbit 
p-tau Life Technologies MN1060 
AT100 
mouse 
p-tau Life Technologies MN1020 
AT8 
mouse 
⍺ -synuclein Invitrogen 32-8100 mouse 
⍺ -synuclein Abcam ab27766 mouse 












⍺ /β-synuclein Synaptic Systems 128002 rabbit 






catalogue number / clone host 
MAP2 Abcam ab11267 mouse 
monoclonal 
A11 Invitrogen AHB0052 rabbit 
polyclonal 
OC Merck AB2286 rabbit 
polyclonal 
 
4.4. Coverslip preparation 
Thin coverslips (<100 µm, Gerhard Menzel) used for all experiments were acid-cleaned (1 M HCl 
overnight, then 1 M NaOH for 45 minutes). The coverslips were extensively washed with deionized 
water after each acid or base incubation. The coverslips were stored in 100% EtOH until flaming 
prior to overnight coating with poly-L-lysine (PLL; 0.1 mg/ml).  
4.5. Cell culture 
4.6.1. PC12 cells 
PC12 cells - derived from pheochromocytoma of the rat adrenal medulla (Heumann et al., 1983) - 
were cultured in standard Dulbecco’s modified Eagle’s medium (DMEM, Lonza) enriched with 
10% horse serum (Merck), 5% fetal calf serum (PAA), 4 mM L-glutamine (Sigma-Aldrich), and 
100 U/ml each of penicillin and streptomycin (Lonza) at 37ºC, 5% CO2, 90% humidity. Cells were 
seeded on PLL-coated coverslips of 18 mm diameter 24 hours prior to the experiment. For 
passaging, the cells were harvested by trypsin/EDTA (Lonza) treatment.  
4.6.2. COS-7 cells 
COS-7 cells - green monkey kidney fibroblast-like cells transformed by the simian virus 40 (SV40, 
Invitrogen) - were cultured in standard DMEM enriched with 10% fetal calf serum, 2 mM L-
glutamine, and 100 U/ml each of penicillin and streptomycin at 37ºC, 5% CO2, 90% humidity. 
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Cells were seeded on PLL-coated coverslips of 18 mm diameter 24 hours prior to the experiment. 
For passaging, the cells were harvested by trypsin/EDTA treatment.  
4.6.3. Neuronal culture 
Primary hippocampal neurons of newborn rats were seeded on a previously grown astrocyte layer 
on PLL-coated coverslips of 18 mm diameter. The neurons were cultured in Neurobasal A 
(Invitrogen) enriched with 2% B27 (Invitrogen), 1% glutamax-I (Invitrogen), 60 U/ml penicillin, 
and 20 U/ml streptomycin at 37ºC, 5% CO2, 90% humidity.  
4.6. Fluorescence in situ hybridization (FISH) 
4.6.1. Probe design 
All DNA oligonucleotides were purchased from Eurofins. The probes were designed to have similar 
hybridization properties using a custom MatLab (The Mathworks Inc) macro to find all non-
overlapping sequences of 55 nucleotides with a GC content between 45.5% and 56.4%. Those 
candidates were checked for possible cross-reactions by aligning their sequences against the rat 
mRNA database (RefSeq, NCBI database). All candidates with more than 25% of their sequence 
reverse complementary to unspecific targets were removed. Sequences spanning contiguous exons 
were preferred to detect mature mRNAs specifically. The probes were labeled with one Atto647N 
fluorophore at each end. This increased the signal while avoiding self-quenching of the fluorophore 
and alteration of the hybridization properties. Three probes were chosen for each target resulting in, 
in theory, three probes with six fluorophores per target mRNA molecule. A list of the probes used 
can be viewed in the subsequent table (Table A). 
(C) Table | List of FISH probes with their sequences and fluorophores.  
target mRNA (probe name) probe sequence (all sequences from 5’ to 3’) 
β-actin (coding sequence; act#1) TTC TCC ATA TCG TCC CAG TTG GTT ACA ATG CCG TGT TCA ATG GGG TAC TTC AGG G 
β-actin (coding sequence; act#2) AGG TCT CAA ACA TGA TCT GGG TCA TCT TTT CAC GGT TGG CCT TAG GGT TCA GAG G 
β-actin (coding sequence; act#3) ACC AGA CAG CAC TGT GTT GGC ATA GAG GTC TTT ACG GAT GTC AAC GTC ACA CTT C 
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target mRNA (probe name) probe sequence (all sequences from 5’ to 3’) 
synaptophysin (coding sequence; syp#1) TTG AAC ACG AAC CAT AAG TTG CCA ACC CAG AGC ACC AGG TTC AGG AAG CCA AAC A 
synaptophysin (coding sequence; syp#2) GTG TAG CTG CCA CAC GTA GCA AAG GCG AAG ATG GCA AAG ACC CAC TGC AGC ACC T 
synaptophysin (coding sequence; syp#3) GCA TCT CCT TGA TAA TGT TCT CTG GGT CCG TGG CCA TCT TCA CAT CGG ACA GGC C 
synaptophysin (UTR; syp_utr#1) AAC AGC AAA GAC AGT TAG GGT CTC CTG GGT TGA GGG GTG GAG ACC TAG GAT ATG G 
synaptophysin (UTR; syp_utr#2) TCC TCT CTC TAC AGA GGT TAT CTC CTC TCT GCC CGT TTC ACC CAA GCC TCC TCC A 
synaptophysin (UTR; syp_utr#3) GAG CCC GCT GTG TTT AAG CCA CAC CCC TCC TAG AAC CAC TCT CTC TGG TCA CTT A 
synaptotagmin (coding sequence; syt#1) CAT AAA CTT CTG CTT CAG CTT GGA AAA GGC ATC TTC CTT CCC TTC CCC AGG ACT G 
synaptotagmin (coding sequence; syt#2) CTG GAG ATC ACG CCA CTC CTC GGT CAC ATG GCC AAA ATC CAC GGT GTT CAT AGG A 
synaptotagmin (coding sequence; syt#3) GCC CCA GTG CTG TTG TAA CCA ACG AAG ACT TTG CCG ATG GCG TCG TTC TTG CCA A 
synaptotagmin (UTR; syt_utr#1) CAA AGT CTT CCG ATC TGA CTG CGG ATG TTG GTT GCT CAA GCG CTT TCA AGT CTT C 
synaptotagmin (UTR; syt_utr#2) CTC GGA ATC TTT CTT CAA TCT TAA TGA GAC GTT CTG GTG GCG CTC TGG GGA TGG C 
synaptotagmin (UTR; syt_utr#3) ACA GAT ACT GGC TAA AGA GCA CTA TGT GGG CAG ATG CAG AAA GGC TTC GTT TTC C 
synaptobrevin (coding sequence; syb#1) AGA TGA TCA TCA TCT TGA GGT TTT TCC ACC AGT ATT TGC GCT TGA GCT TGG CTG C 
synaptobrevin (coding sequence; syb#2) CAT CCA CCT GGG CCT GGG TCT GCT GCA GTC TCC TGT TAC TGG TAA GAT TTG GAG G 
synaptobrevin (coding sequence; syb#3) CGA TCA TCC AGT TCC GAT AGC TTC TGG TCC CGC TCC AGG ACC TTG TCC ACA TTC A 
synaptobrevin (UTR; syb_utr#1) TAA CAG CTG GCT ATT TAC AGG GGG CAC ACA CAC GGA CAC ACA CAC ACA CGG ATC C 
synaptobrevin (UTR; syb_utr#2) GGG GTT TGC TCT GTT TGG GGA GGG TCT GGA ATT GTA CAG GGA AGA TAG GGG AAG G 
synaptobrevin (UTR; syb_utr#3) GAG GCT CCC AAG GGA TAC AAA GAT GCA ACC TAT GGA AGC CTA GAC AGG TGG GGT G 
random control probes (rnd#1) TTA AAC ACA ACG ACG ACC GGG AAC AAT CAT TAT GGC ACG CGG AGC AAT GGC TAA C 
random control probes (rnd#2) AGA CGC AAC AAG ATT ACG TAC GCG AAC GAA GTA CGC ACG TCA GGT TCA AAT CGC A 




4.6.2. Immunostaining of cells (after FISH) 
After the last rinse with 1x SSC during the FISH procedure, the cells were fixed with 4% 
paraformaldehyde (PFA) and quenched again, as described previously. The cells were then 
permeabilized with 0.1% Triton-X (Merck) in PBS for 5 minutes. Primary and secondary antibodies 
were diluted 1:250 and 1:1000, respectively, in 1.5% bovine serum albumin (BSA) and 0.1% 
Triton-X in PBS. Guinea pig anti-synaptophysin and mouse anti-MAP2 antibodies were incubated 
prior to fluorescently labeled secondary antibodies. Each antibody incubation of 1 hour was 
followed by extensive washings with PBS. The cells were then embedded in Mowiol and stored as 
described above.  
4.7. Immunostaining of CSF 
4.7.1. Synthetic Aβ samples 
Aβ4-38 and Aβ1-42 peptides were dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP, PSL), flash-
frozen in liquid nitrogen, and then lyophilized to completely remove the solvent. Lyophilized Aβ 
peptides were re-dissolved in 100 mM NaOH at a concentration of 2 mg/ml, aliquoted, flash-frozen 
with liquid nitrogen, and stored at -80ºC until use. Size-exclusion chromatography (SEC) was 
performed using a Superose 6 10/300 column (GE Healthcare) connected to an ÄKTApurifierTM 10 
UPC 900 system (GE Healthcare). The samples were prepared in phosphate buffer (50 mM, pH 7.4) 
with 50 mM NaCl, at a peptide concentration of 0.5 mg/µl and then incubated at 37ºC for 24 h, 
without further promotion of aggregation by agitation. After a short centrifugation step, 250 µl of 
peptide solution was loaded onto the column at a flow rate of 0.5 ml/min. The peptide elution was 
monitored by UV absorbance at 215 and 265 nm. The SEC peaks were calibrated and 
corresponding stoichiometries were calculated as previously published (Paivio et al., 2004). Aβ4-38 







4.7.2. Human subjects 
Cerebrospinal fluid (CSF) was collected and stored at one clinical center according to one standard 
operation procedure (SOP) to minimize storage and sample handling artifacts. CSF was obtained 
from the Biobank at the Department of Psychiatry (University Medical Center). Patients with 
Alzheimer’s Disease (AD) and mild cognitive impairment (MCI) were clinically phenotyped by 
neuropsychological testing (CERAD Plus test battery as the minimum assessment), neurological 
examination, MRI, and CSF diagnostics by the Memory Clinic’s specialized physicians (University 
Medical Center). AD diagnosis was based on the criteria of the National Institute of Neurological 
and Communicative Disorders and Stroke and the Alzheimer’s Disease and Related Disorders 
Association (NINCDS-ADRDA). Patients with preserved activities of daily living but showing a 
combination of memory complaints plus a performance of 1-1.5 standard deviations below the age 
norm on at least one cognitive domain of the CERAD Plus test battery were considered as MCIs 
(Winblad et al., 2004). Control samples were provided by the Departments of Psychiatry and 
Neurology (University Medical Center) including patients with schizophrenia, bipolar disorder, 
depression, multiple sclerosis, and headache. Patients of the control group with memory deficits 
(e.g. due to negative symptoms caused by schizophrenia) were neuropsychologically assessed and 
patients with dementia or neurodegenerative diseases were excluded from controls. Biosampling 
was conducted according to the Declaration of Helsinki and was approved by the ethics committee 
of the University Medical Center Göttingen (approval number 2/5/09) and all patients gave 
informed written consent. For detailed information, please refer to Tables B-E.  
4.7.3. CSF samples 
CSF samples were collected at the memory clinic and the Department of Psychiatry (University 
Medical Center) starting in 2010, following identical SOPs. In short, CSF was obtained between 9 
a.m. and 1 p.m. and centrifuged for 10 minutes at 2000x g and room temperature within 20 minutes 
after the lumbar puncture. The supernatant was then aliquoted, flash frozen, and stored at -80ºC. 
CSF samples containing blood contamination were excluded.  
Six post-mortem CSF samples from confirmed AD patients were obtained from the Tissue Bank, 
Fundación CIEN (Instituto de Salud Carlos III). Rapid brain autopsies were performed according to 
the brain bank protocol (Martinez-Martin et al., 2010). CSF (10-15 ml on average) was obtained 
during autopsy by puncture of the IIIrd ventricle through its floor, immediately behind the optic 
chiasm before removal of the brain. The CSF was assessed regarding to its color and macroscopic 
 
 54 
properties, as well as its pH was measured. The CSF samples were subsequently centrifuged for 8 
minutes at 1300x g and 4ºC. 0.5-1 ml aliquots of the supernatant were prepared and stored as stated 
above.  
Enzyme-linked immunosorbent assay (ELISA) measurements of these samples were performed 
commercially (Universitätsklinikum Tübingen) according established methods. The quantities of 
Aβ1-42 and tau were determined and are shown in Tables B-E.  
(D) Table | Patient information and CSF properties from controls. 
ID diagnosis sex age Abeta tau  FAβ 
      [years] [pg/ml] [pg/ml]   
63 fragile X m 20 576 91 45.616 
67 polyneuropathy f 64 669 175 3.794 
78 multiple sclerosis f 60 240 979 56.714 
92 schizophrenia m 59 440 197 63.227 
101 schizophrenia m 49 469 190 3.594 
106 multiple sclerosis m 57 781 290 37.753 
120 severe depression f 57 622 347 55.442 
126 schizophrenia m 42 1265 365 54.643 
130 schizophrenia m 19 790 202 47.392 
131 severe depression m 60 632 339 35.724 
132 schizophrenia f 34 518 154 5.028 
135 severe depression m 48 809 217 27.836 
138 anxiety, depression f 48 621 214 42.764 
140 depression f 63 828 613 40.098 
151 schizophrenia f 42 654 150 35.071 
161 severe depression f 24 182 788 49.997 
166 severe depression m 48 452 97 41.773 
167 schizophrenia m 20 690 136 46.549 
172 schizophrenia f 55 915 226 50.501 
173 schizophrenia m 23 914 287 48.022 
177 severe depression m 54 1006 296 44.856 
 
(E) Table | Patient information and CSF properties from AD patients. 
ID sex 
age  
MMSE Abeta [pg/ml] 
tau 
[pg/ml] FAβ FAβ, tau [years] 
4 m 70 23 423 136 2.747 12.933 
6 f 69 9 275 927 2.585 12.576 
16 m 79 26 170 424 36.484 16.928 
22 m 58 17 613 109 29.683 14.698 
47 m 64 27 334 422 42.355 16.676 
57 m 73 22 269 253 15.997 0.9657 
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60 f 78 21 223 346 37.072 14.241 
61 f 59 17 229 832 16.045 10.675 
65 f 83 6 260 342 12.268 0.9709 
69 m 72 22 215 477 10.848 0.8931 
73 m 74 22 220 368 30.845 16.877 
76 m 63 25 311 425 28.863 15.778 
84 f 74 27 285 327 30.735 11.852 
89 f 54 20 135 725 11.943   
98 f 76 24 489 422 37.647 16.408 
107 f 78 22 224 542 37.069 16.408 
111 m 62 27 316 828 33.758 15.455 
112 f 72 25 12 140 49.645 19.203 
114 f 69 26 439 323 31.976 16.496 
115 m 71 28 307 424 24.652 22.336 
116 f 82 23 402 173 28.853   
119 f 71 22 130 923 29.686 15.421 
123 f 75 23 443 832 46.084 14.502 
124 f 72 23 155 1033 46.037 13.553 
141 f 57 28 638 616 15.024   
144 m 73 27 368 652 48.801   
145 m 79 28 917 374 48.196   
148 f 75 27 153 272 21.772   
159 m 67 21 567 152 51.414   
163 m 77 25 396 236 50.351   
 
(F) Table | Patient information and CSF properties from AD cases confirmed by autopsy. 
ID sex 
age  
FAβ FAβ, tau [years] 
48 f 84 0.9168 0.8542 
190 m 94 0.6843 22.187 
213 f 91 1.582 14.741 
1742 f 82 12.355 15.842 
1749 f 67 16.383 1.258 









(G) Table | Patient information and CSF properties from mild cognitive impaired (MCI). The 





FAβ FAβ, tau [years] [pg/ml] [pg/ml] 
59* f 78 29 160 410 29.371 12.855 
72 m 65 28 327 617 24.176 12.979 
74 m 70 27 254 286 29.023 1.448 
80 m 54 26     23.497 11.403 
81 m 71 25 336 1147 1.349 0.9682 
83 m 70 27 474 188 64.559 23.248 
86 m 59 30 286 178 58.355 21.622 
91 m 71 30 561 327 49.994 17.832 
94 f 67 28 837 150 36.526 14.384 
95* f 74 28 235   45.476 15.715 
164 m 64 29 881 424 45.028   
 
4.7.4. Immunostaining 
Freshly prepared PLL-coated coverslips were briefly washed with PBS and CSF samples were 
immediately added for 30 minutes in a humidifying chamber. The CSF was then fixed with 4% 
PFA for 25 minutes and quenched with 0.1 M NH4Cl for 10 minutes. Unless otherwise stated, the 
samples were blocked for 30 minutes with 5% BSA and 5% peptone in PBS. The CSF was 
immunostained with the respective primary antibody in blocking solution for one hour. Excess 
antibodies were removed by three washings with PBS for 5 minutes each before 1 hour incubation 
with secondary Fab fragments coupled to Atto647N fluorophores in blocking solution. The 
coverslips were subsequently rinsed three times with high salt PBS and twice with PBS for 5 
minutes each. The coverslips were embedded and stores as described above.  
4.8. Epifluorescence imaging 
Wide-field fluorescence images were taken at an Olympus IX71 microscope (Olympus) equipped 
with an 100x oil TIRFM objective (1.45 numerical aperture, NA; Olympus) and an F-View II 
charge-coupled device (CCD) camera (1376 pixels x 1032 pixels with a pixel size of 6.45 µm x 




(H) Table | List of filter cubes for epifluorescence imaging.  
filter excitation beamsplitter emission 
DAPI 350/50 D 400 DCLP 460/50 D 
FITC 480/40 HQ 505 LP Q 527/30 HQ 
TRITC 545/30 HQ 570 LP Q 610/75 HQ 
Cy5 620/60 HQ 660 LP Q 700/75 HQ 
 
4.9. Confocal and STED imaging 
Confocal and STED images were taken at a Leica TCS SP5 STED microscope (Leica) with a 100x 
HCX PL APO CS oil objective (1.4 NA; Leica). A 635 nm pulsed diode laser (Leica) was used for 
excitation. To create the super-imposed donut for depletion, a Spectra-Physics MaiTai multiphoton 
laser at 750 nm (pulsed at 80 MHz, ~1.3 W output power with the 100x objective, Titanium 
Sapphire; Newport Spectra-Physics) was used. For multichannel confocal imaging, the following 
settings were used: Argon laser at 488 nm for GFP, Cy2, or autofluorescence; Helium-Neon lasers 
at 594 nm or 633 nm for Cy3 or Atto647N, respectively. Images were taken sequentially line by 
line at a scanning frequency of 1000 Hz with 16 or 32 times for confocal and 96 times line 
averaging for STED mode. Fluorescence was detected by photomultiplier tubes (PMT) for confocal 
or by an avalanche photodiode (APD) for STED images using laser intensities with the best signal-
to-noise ratio for each experiment. The STED resolution ~50 nm.  
4.10. Image analysis 
All analyses were performed using custom-written macros (mostly developed by Silvio O. Rizzoli) 
for MatLab (Mathworks). For better visibility, STED images were deconvolved with  Huygens 
Essential 3.3 (Scientific Volume Imaging) using a classical maximum likelihood estimation 
(CMLE) algorithm. 
4.11. Statistics 
All data is presented as mean ± SEM, unless stated otherwise. SigmaPlot (Mathworks) was used for 
student’s t-test (unpaired) and the p-values were obtained. Statistical significance is denoted as non-
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